ArticlePharmacoEconomics - open2024

Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina.

Carlos Rojas-Roque et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.